Further Observations on the Unique Efficacy of Picotesla Range Magnetic Fields in Parkinson's Disease

References

• Boyd A. E., Reichlin S., Turksoy N. Galactorrhoea-amenorrhoea syndrome: diagnosis and therapy. Annuals of Internal Medicine 1977; 87: 165–175
   PubMed Web of Science ®Google Scholar
• Celesia G. C., Wanamaker W. M. Psychiatric disturbances in Parkinson's disease. Diseases of the Nervous System 1972; 33: 577–583
   PubMedGoogle Scholar
• Charcot J. M. Cinquieme Lecon: De la paralysie agitante. Lecons sur les maladies du systeme nerveux faites a la Salpetriere, D. M. Bourneville. A Delahaye., Paris 1872
   Google Scholar
• Damasio A. R., Lobo-Antunes J., Macedo C. Psychiatric aspects in parkinsonism treated with L-dopa. Journal of Neurology Neurosurgery and Psychiatry 1981; 34: 502–507
   Google Scholar
• Dovoisin K. C. The differential diagnosis of parkinsonism. Parkinson's disease, G. Stern. Chapman and Hall Medical., London 1990; 431–466
   Google Scholar
• Fanget F., Claustrat H., Dalery J., Brun J., Terra J. L., Marie-Cardine M., Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25: 499–501
   PubMed Web of Science ®Google Scholar
• Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in Parkinson's disease. Journal of Neural Transmission 1991; 3: 41–47
   Web of Science ®Google Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Goodwin F. K., Murphy D. L., Brodie H. K. H., Bunney W. E. Levodopa: alterations in behaviour. Clinical Pharmacology and Therapeties 1971; 12: 383–396
   PubMedGoogle Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset. Progression and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Hunker C. J., Abbs J. H., Barlow S. M. The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: a quantitative analysis. Neurology 1982; 32: 749–755
   PubMed Web of Science ®Google Scholar
• Janković J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. Handbook of parkinsea's disease, W. C. Koller, 1987; 99–126
   Google Scholar
• Janković J. What is Parkinson's disease. Parkinson Report 1992; 13(issue III)1–4
   Google Scholar
• Jellinger K. Overview of morphological changes in Parkinson's disease. Advances in neurology, M. D. Yahr, K. J. Bergmann. Raven Press., New York 1986; 1–18
   Google Scholar
• Karson C. N., Stauh R. A., Kleinman J. E., Wyatt R. J. Drug effect on blink rates in rbesus monkeys: preliminary studies. Biological Psychiatry 1981; 16: 249–254
   PubMed Web of Science ®Google Scholar
• Karson C. N., Freed W. J., Kleinman J. E., Bigelow L. B., Wyatt R. J. Neuroleptics decrease blinking in schizophrenic subjects. Biological Psychiatry 1981; 16: 679–682
   PubMed Web of Science ®Google Scholar
• Koller W. C., Hubble J. P. Levodopa therapy in Parkinson's disease. Neurology 1990; 40: 40–47, suppl 3
   Google Scholar
• Lewy A. J., Sack R. L., Singer C. M. Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve. Psychopharmacology Bulletin 1984; 20: 561–565
   PubMedGoogle Scholar
• Marsh G. G., Markham C. H. Does levodopa alter depression and psychopathology in parkinsonian patients. Journal of Neurology, Neurosurgery and Psychiatry 1973; 36: 925–935
   PubMedGoogle Scholar
• Mayeux R. Mental state. Handbook of parkinson's disease, W. C. Koller. Marcel Dekker., New York 1987; 127–144
   Google Scholar
• Mayeux R., Stern Y., Cote L., Williams J. H. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. American Journal of Psychiatry 1986; 143: 756–750
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813–1814
   PubMed Web of Science ®Google Scholar
• Mindham R. H. S. Psychiatric symptoms in parkinsonism. Journal of Neurology Neurosurgery and Psychiatry 1970; 33: 188–191
   PubMed Web of Science ®Google Scholar
• Paulson G. W. Management of patients with Parkinson's disease who fail to respond to levodopa. Continuing Education, May issue 1986; 234–240
   Google Scholar
• Pearce J. Mental changes in parkinsonism. British Medical Journal 1974; 2: 445
   PubMed Web of Science ®Google Scholar
• Raft D., Newman M., Spencer R. Suicide on L-dopa. Southern Medical Journal 1972; 65: 312
   PubMedGoogle Scholar
• Sandyk R. Pineal melatonin functions and the depression of Parkinson's disease. International Journal of Neuroscience 1990; 50: 31–53
   Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on-off” phenomenon. International Journal of Neuroscience 1992; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of Parkinsonism. International Journal of Neuroscience 1992; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R., Derpapas K. The effects of external pico Tesla range magnetic fields on the EEG in Parkinson's disease. International Journal of Neuroscience, in press a
   Google Scholar
• Sandyk R., Derpapas K. Magnetic fields normalize visual evoked potentials and brain-stem auditory evoked potentials in multiple sclerosis. International Journal of Neuroscience, in press b
   Google Scholar
• Sandyk R., Anninos P. A., Tsagas N., Derpapas K. Magnetic fields in the treatment of Parkinson's disease. International Journal of Neuroscience 1992; 63: 141–150
   PubMed Web of Science ®Google Scholar
• Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–1133
   PubMed Web of Science ®Google Scholar
• Schiffer R. B., Kurlan R., Rubin A., Boer S. Evidence for atypical depression in Parkinson's disease. American Journal of Psychiatry 1988; 145: 1020–1022
   PubMed Web of Science ®Google Scholar
• Selby G. Clinical features. Parkinson's disease, G. Stern. Chapman and Hall Medical, London 1990; 333–388
   Google Scholar
• Semm P. Pineal function in mammals and birds is altered by earth-strength magnetic fields. Electromagnetic fields and circadian rhythmicity, M. C. Moore-Ede, S. S. Campbell, R. J. Reiter. Birkhauser., Boston 1992; 53–62
   Google Scholar
• Snider S. R., Sandyk R. Sensory dysfunction. Handbook of parkinson's disease, W. C. Koller. Marcel Dekker., New York 1987; 171–180
   Google Scholar
• Tanner C. M., Goetz C. G., Klawans H. L. Autonomic nervous system dysfunction. Handbook of Parkinson s disease, W. C. Koller. Marcel Dekker., New York 1987; 145–170
   Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effect of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Whitlock F. A. The psychiatric complications of Parkinson's disease. Australian and New Zealand Journal of Psychiatry 1986; 20: 114–121
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Anderson L. E., Hilton D. I., Phillips R. D. Chronic exosure to 60-Hz electric fields: effects on pineal function in the rat. Bioelectromagnetics 1981; 2: 371–380
   PubMed Web of Science ®Google Scholar